NCT00007423View on ClinicalTrials.gov

Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2001

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

Trial Locations (2)

Unknown

UVRI - IAVI HIV Vaccine Program, Entebbe

Joint Clinical Research Center N09-002 CRS, Kampala

Sponsors
All Listed Sponsors
collaborator

Joint Clinical Research Center

OTHER

collaborator

MRC/UVRI and LSHTM Uganda Research Unit

OTHER

collaborator

Joint UN Programme on HIV/AIDS (UNAIDS)

OTHER

collaborator

Fogarty International Center of the National Institute of Health

NIH

collaborator

Case Western Reserve University

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH